Emory Alzheimer's Disease Research Center

埃默里阿尔茨海默病研究中心

• 批准号: 10212229
• 负责人: JAMES J LAH
• 金额: $ 46.88万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10212229
• 关键词: African American; Alzheimer' s Disease; Alzheimer' s disease related dementia; Area; Automobile Driving; Biological Markers; Biology; Blood Vessels; Cardiovascular Physiology; Cardiovascular system; Caucasians; Clinical; Clinical Research; Clinical Trials Unit; Collection; Data Analyses; Dementia with Lewy Bodies; Development; Diagnostic; Disease; Enrollment; Etiology; Foundations; Funding; Goals; Individual; Institution; International; Lead; Lewy Body Disease; Lewy body pathology; Link; Longitudinal cohort; Measures; Medicine; Minority; Molecular; Movement Disorders; Parkinson Disease; Parkinson' s Dementia; Participant; Phenotype; Play; Positioning Attribute; Procedures; Process; Recommendation; Research; Research Activity; Research Project Grants; Role; System; Training Activity; United States National Institutes of Health; Validation; Vascular Cognitive Impairment; Work; biomarker discovery; clinical center; clinical phenotype; cohort; data management; data sharing; follow-up; improved; neuropathology; new therapeutic target; novel marker; operation; outreach; racial disparity; recruit; research and development; research study; sample collection; success; symposium; tool; vascular factor

SUMMARY/ABSTRACT: CLINICAL CORE The primary goals of the Clinical Core are to support and enhance research efforts of the Goizueta Alzheimer’s Disease Research Center (ADRC) at Emory to advance cutting-edge research to identify novel biomarkers and therapeutic targets while reducing racial disparities in AD research. The Clinical Core plays a central role in the Goizueta ADRC by engaging diverse research participants and driving activities that reflect the Center’s overall themes. To accomplish these goals, the Clinical Core has well-established processes to recruit, track, characterize, and retain a cohort of longitudinal research participants and to effectively coordinate activities and share data with other components of the ADRC and external partners. In the current funding period, the Clinical Core established a Longitudinal Biomarker Collection to support high-priority multicenter research projects, including the Accelerating Medicine Partnership for AD (AMP-AD) and Molecular Mechanisms of the Vascular Etiology of AD (M2OVE-AD). Successful development of the LBC led to a competitive supplement to establish a Biomarker Core which will continue as a Core component in the ADRC renewal. Also, during the current cycle, we succeeded in our ambitious goal for increasing the diversity of our UDS cohort by enrolling an equal number of new African-American and Caucasian participants. This success supported the establishment of a Minority Engagement Core (MEC). Specific Aims for this renewal are to 1) Establish and maintain a diverse cohort of well-characterized research participants to support priorities in current ADRD research; 2) Advance biomarker discovery efforts by harmonizing procedures for sample collection and clinical phenotyping across multiple related projects and cohorts; and 3) Expand and integrate activities in ADRD, including vascular cognitive impairment and Lewy body diseases. Achieving these Specific Aims will advance the priorities identified in the National Alzheimer’s Project Act (NAPA) and recommendations from the NIH ADRD Research Summits, and will ultimately lead to effective diagnostic tools and treatments for individuals suffering from AD and related disorders.

摘要/摘要：临床核心